skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

New class of agents for treatment of hypertension: Focus on direct renin inhibition

Review

(3279) Views  (1496) Full article downloads

Authors: Roberto Fogari, Annalisa Zoppi

Published Date October 2010 Volume 2010:6 Pages 869 - 882
DOI: http://dx.doi.org/10.2147/VHRM.S4189

Roberto Fogari, Annalisa Zoppi
Department of Internal Medicine and Therapeutics, University of Pavia, Italy

Abstract: Aliskiren, the first orally active direct renin inhibitor, is an effective antihypertensive drug with distinctive characteristics, including good blockade of the renin-angiotensin system, a prolonged duration of action, pharmacologic effects that persist after drug discontinuation, and favorable tolerability comparable with placebo. The blood pressure-lowering effect of aliskiren monotherapy is similar, if not superior, to that of other first-line antihypertensive agents, and is greatly enhanced when aliskiren is combined with various other antihypertensive medications, without any adverse drug interactions. Aliskiren is also an effective and well tolerated therapy in special populations, including diabetic, obese, and elderly hypertensives. Beyond its blood pressure-lowering efficacy, results from experimental and clinical trials suggest that aliskiren has positive effects on markers of cardiovascular and renal damage. The ASPIRE (Aliskiren Study in Post-MI patients to Reduce rEmodelling) HIGHER clinical trials program is further assessing whether the promising pharmacologic properties of aliskiren translate into reduced risk of adverse cardiovascular and renal outcomes.

Keywords: aliskiren, renin inhibitors, hypertension, treatment






Readers of this article also read:

Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
Antiatherogenic effects of vitamin E: the search for the Holy Grail
Angiotensin II receptor blockers in the prevention of complications from atrial fibrillation
On the antiatherogenic effects of vitamin E: the search for the Holy Grail
Cardiac risk stratification: Role of the coronary calcium score
Patient perspectives on use of long-acting antipsychotics in bipolar disorder: focus on risperidone injection
Effectiveness of coordination exercise in improving cognitive function in older adults: a prospective study
Effect of vascular burden as measured by vascular indexes upon vascular dementia: a matched case-control study
New treatment options in the management of hypertension: appraising the potential role of azilsartan medoxomil
Cardiac ryanodine receptor in metabolic syndrome: is JTV519 (K201) future therapy?
  • Join ISVH

    Be part of the World's leading experts in vascular health by joining the International Society of Vascular Health (ISVH)

  • Testimonials

    "... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University